Akeso Biopharma of Zhongshan Closes $45 Million B Round

Akeso Biopharma, a Zhongshan antibody company, closed a $45 million B round, led by the GTJA Investment Group. Founded in 2012, Akeso uses 3D simulations of its antibody candidates to improve their affinity for a target. The company says the process can improve affinity by as much as 100 times. Two years ago, Merck agreed to a $200 million package of milestones in return for global rights to an Akeso immune checkpoint antibody. Akeso is currently developing 25 research projects involving drugs for oncology, inflammation, autoimmune and cardiovascular diseases. More details.... Share this with colleagues: // //